The Treatment Action Campaign (TAC) is celebrating what it calls a “ground-breaking” decision on Thursday by the Competitions Commission that found two giant pharmaceutical firms culpable of charging excessive prices for anti-retroviral drugs and abusing their dominant positions in the market. The firms, GlaxoSmithKline South Africa and Boehringer Ingelheim, will have to appear before the Competitions Tribunal - the commission's prosecuting arm - to defend their contravention of the Competitions Act.